DV
Dividend Vision

NVNO — enVVeno Medical Corp

enVVeno Medical Corp (NVNO)

Total return is -99.8% over the past 8.2 years, 324.9 points behind SPY at 225.1%. Its deepest 1-year drawdown was 95.0%.

enVVeno Medical Corporation is a medical device company developing bioprosthetic tissue-based solutions for treating venous disease, with its lead product being the VenoValve, a surgical replacement venous valve for chronic venous insufficiency, along with enVVe, a transcatheter-based replacement venous valve system in development. The company does not currently distribute to shareholders. enVVeno appeals to investors seeking exposure to medical device innovation in the venous disease treatment market, though as a pre-revenue or early-stage company it carries higher risk typical of development-stage healthcare firms.

NVNO key facts

Asset type
Stock
Asset class
Equity
Inception date
05/31/2018
Last close
$10.99
Market cap
$6,776,840
Average volume
1491.0
Payment date
11/30/2020
Beta
1.089
Payout ratio
0.0
Forward P/E
0.0
EPS
$-31.20